|
May 13
|
Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates
|
|
May 3
|
Galera Adopts Limited Duration Stockholder Rights Agreement
|
|
Mar 28
|
Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates
|
|
Aug 10
|
Galera shares plunge 85% on FDA rejection; workforce cut by more than half
|
|
Aug 9
|
Galera shares tank after US FDA declines to approve inflammation disease drug
|
|
Aug 9
|
Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese
|
|
Apr 26
|
Galera to Present One-Year Reductions in Cisplatin-Related Chronic Kidney Disease Data from ROMAN Trial at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
|